Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating expenses:
Research and development	$ 99,323	$ 106,043
General and administrative	28,292	26,533
Goodwill impairment	0	19,462
Total operating expenses	127,615	152,038
Loss from operations	(127,615)	(152,038)
Interest income	10,714	9,978
Interest expense	(4)	(25)
Other expense, net	(217)	(573)
Loss before income tax provision	(117,122)	(142,658)
Income tax provision	0	0
Net loss	$ (117,122)	$ (142,658)
Net loss per share attributable to common stockholders, basic	$ (1.33)	$ (3.31)
Net loss per share attributable to common stockholders, diluted	$ (1.33)	$ (3.31)
Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, basic	87,866,435	43,042,405
Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, diluted	87,866,435	43,042,405
Other comprehensive loss:
Unrealized gain on treasury securities, net of tax	$ 16	$ 0
Total other comprehensive loss	16	0
Comprehensive loss	$ (117,106)	$ (142,658)